<DOC>
	<DOCNO>NCT01593670</DOCNO>
	<brief_summary>This Phase II therapeutic trial combine Decitabine day 1-5 oral Vorinostat twice daily day 6-15 followed single infusion CD3-/CD19- enrich donor natural killer ( NK ) cell day 17 short course Interleukin-2 ( IL-2 ) facilitate NK cell survival expansion . Two course treatment give separate 6-8 week . The intent administer treatment outpatient setting .</brief_summary>
	<brief_title>Decitabine Vorinostat Conditioning Followed CD3-/CD19- NK Cells Infusion High Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>A single donor apheresis collect day 15 cycle 1 , enrich NK cell large scale CliniMacs device ( Miltenyi ) activate overnight incubation IL-2 . After wash , final NK cell product divide two , half give fresh day 17 course # 1 half store frozen day 17 course # 2 . Clinical response formally assess 4-6 week start 2nd course base International Working Group ( IWG ) criterion ; however , bone marrow evaluation complete assess sign significant disease progression cycle 1 2 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Diagnosis high risk myelodysplastic ( MDS ) meet one follow disease classification require treatment : International Prognostic Scoring System ( IPSS ) Category : INT2 High Risk WHO Classification : RAEB1 RAEB2 High risk cytogenetic abnormality define presence Monosomy 7 , complex karytope , monosomal karyotype WHO Based Prognostic Scoring System ( WPSS ) : High Very High Risk Patients may untreated maximum 2 cycle hypomethylating agent ( azacitidine decitabine ) without evidence treatment failure define progression advance MDS Who classification AML . Patients must receive treatment MDS within 4 week begin trial . Treatments allow prior time include azacitidine decitabine hematopoietic growth factor . No prior AMLlike induction therapy allow . Age â‰¥ 18 year age Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Available related HLAhaploidentical NK cell donor least Class I serologic type A &amp; B locus Have acceptable organ function within 14 day enrollment Ability prednisone immunosuppressive drug least 3 day prior natural killer ( NK ) cell infusion Women child bear potential must agree use effective method contraception Voluntary write consent Pregnant lactating . Prior 7 + 3 ( cytarabine give continuously 7 day anthracycline drug , daunorubicin idarubicin give 1st 3 day treatment ) AMLtype induction chemotherapy New progressive pulmonary infiltrates screen chest xray chest compute tomography ( CT ) scan evaluate bronchoscopy ( feasible ) Uncontrolled bacterial viral infection chronic asymptomatic viral hepatitis allow Pleural effusion moderate large size detectable chest xray Known hypersensitivity one study agent Prior hypomethylating treatment great 2 cycle document treatment failure Prior use histone deacetylase inhibitor Serious medical psychiatric illness likely interfere participation clinical study opinion enrol investigator Inability swallow capsule Active human immunodeficiency virus ( HIV ) Other active potentially life threaten malignancy exclude localize basal squamous cell skin cancer , cervical carcinoma situ , superficial bladder cancer , localize prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>high risk myelodysplastic syndrome</keyword>
	<keyword>natural killer cell</keyword>
</DOC>